SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-15-159288
Filing Date
2015-04-30
Accepted
2015-04-30 08:48:11
Documents
8
Period of Report
2015-04-27
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 2.01: Completion of Acquisition or Disposition of Assets
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d916289d8k.htm 8-K 27963
2 EX-1.1 d916289dex11.htm EX-1.1 35114
3 EX-4.1 d916289dex41.htm EX-4.1 60940
4 EX-5.1 d916289dex51.htm EX-5.1 19477
5 EX-10.1 d916289dex101.htm EX-10.1 217684
6 EX-99.1 d916289dex991.htm EX-99.1 4352
7 GRAPHIC g916289g44n72.jpg GRAPHIC 9737
8 GRAPHIC g916289g90t44.jpg GRAPHIC 17563
  Complete submission text file 0001193125-15-159288.txt   404810
Mailing Address 19820 NORTH CREEK PARKWAY SUITE 201 BOTHELL WA 98011
Business Address 19820 NORTH CREEK PARKWAY SUITE 201 BOTHELL WA 98011 425-686-1500
ONCOGENEX PHARMACEUTICALS, INC. (Filer) CIK: 0000949858 (see all company filings)

IRS No.: 954343413 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 033-80623 | Film No.: 15815476
SIC: 2835 In Vitro & In Vivo Diagnostic Substances